Faculty Profiles - FUJIHARA Kazuya

Papers - FUJIHARA Kazuya

Division display 21 - 40 of about 320 ／ All the affair displays >>

1264-P: Impacts of Diabetes (DM) on Severe Functional Disability (FD) and Care-Need Level Deterioration in Japanese

IZUMI IKEDA, KAZUYA FUJIHARA, HARUKA SHIOZAKI, SAKIKO Y. MORIKAWA, KAHORI TSURUOKA, YAMASHITA YUKO, LAY MON KHIN, SIJIA WU, NORIKO YAGYUDA, CHIKA HORIKAWA, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Avoidance of FD and the deterioration of care level needs leading to a decline in ADL and increased medical costs is urgent. We aimed to clarify the association between lifestyle habits, non-communicable diseases (i.e., DM, HT, and dyslipidemia) and their combinations and the incidence of severe FD and deterioration of the care-level. Followed for a median of 3.7 years were 9673 people who underwent health checkups. Care-level ≥2 (total assistance needed) indicates severe FD and worsening from the initial examination indicates deterioration. During the study period, 111 cases of severe FD occurred. Multivariate analysis showed that aging (per 5y) (OR 2.24 [1.95-2.56]), male (1.76 [1.16-2.66]), BMI&lt;18.5 (2.46 [1.40-4.35]), DM (1.81 [1.06-3.08]), HT (1.58 [1.05-2.38]), and lack of physical activity (PA) (2.17 [1.37-3.45]) were associated with severe FD. Prevalence of DM additively associated with severe FD. DM and ≥2 risk factors had a 10 times greater association than non-DM and no risk factor. Of 85 cases with worsening care needs, only DM was significantly associated with deterioration (2.88 [1.08-7.65]). DM is a significant risk factor for with double the increased risk of severe FD and triple care-need deterioration compared with those without DM. Also, in DM patients, low BMI, HT, and lack of PA greatly increased the risk of severe FD, suggesting the need for comprehensive treatment strategies.

 Disclosure

I. Ikeda: None. K. Fujihara: None. H. Shiozaki: None. S.Y. Morikawa: None. K. Tsuruoka: None. Y. Yuko: None. L. Khin: None. S. Wu: None. N. Yagyuda: None. C. Horikawa: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

DOI： 10.2337/db24-1264-p

researchmap

1372-P: Association between Fat Intake as the Percent of Total Energy and Incidence of Cardiovascular Disease in Persons with Type 2 Diabetes—Japan Diabetes Complication and Its Prevention Prospective Study (JDCP Study)

CHIKA HORIKAWA, MITSUYOSHI TAKAHARA, NAOTO KATAKAMI, YASUNAGA TAKEDA, MIZUKI TAKEUCHI, KAZUYA FUJIHARA, HIROAKI SUZUKI, NARIHITO YOSHIOKA, HITOSHI SHIMANO, JO SATOH, YASUAKI HAYASHINO, NAOKO TAJIMA, RIMEI NISHIMURA, YOSHIMITSU YAMASAKI, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Previous systematic reviews showed benefits of low-carbohydrate eating plans compared with low-fat eating plans in the treatment of diabetes (T2D) on parameters of cardiovascular disease (CVD) risk. However, studies on the relationship between fat intake as the % of total energy (F%E) and incidence of CVD in persons with T2D are insufficient. Therefore, we investigated this relationship as part of the JDCP study, a nationwide study launched in 2007. A total of 1477 persons with T2D aged 40-75 years completed a brief self-administered Diet History Questionnaire at baseline, and we analyzed the resultant data. Primary outcome was the 7-year risk of a CVD event. Hazard ratios for CVD according to quartiles of F%E (Q1-4) were estimated by Cox regression adjusted for confounders including sex, age, various laboratory tests, medication use, smoking history, drinking habits, physical activity, energy intake, protein intake, dietary fiber intake, and sodium intake. Mean F%E in Q1 to Q4 were 16.6%E, 21.8%E, 25.4%E, and 30.9%E, respectively. HbA1c, body mass index, triglycerides, and blood pressure were well controlled. No significant associations between F%E and incidence of CVD were shown for Q2, Q3, and Q4 relative to Q1 (Q2: 1.03 [95% CI, 0.47-2.28], Q3: 1.27 [0.58-2.76], and Q4: 1.10 [0.44-2.73]). Stratified analysis by sex and age also showed no significant difference between F%E and incidence of CVD. When %E from saturated fatty acids (SFA%E) was analyzed according to quartiles 1 and 4 SFA%E values were 4.9%E and 7.1%E, respectively. There were no significant differences in incidence of CVD among quartiles (Q1: Reference, Q2: 1.31 [0.66-2.61], Q3: 0.47 [0.18-1.25], and Q4: 1.02 [0.44-2.39]). Findings suggested that most Japanese with T2D during the study period consumed &lt; 30% of F%E and &lt;10% of SFA%E. No significant differences in incident CVD were observed within these ranges.

Disclosure

C. Horikawa: None. M. Takahara: None. N. Katakami: Speaker's Bureau; Abbott Japan Co., Ltd., Kowa Company, Ltd., MSD, Mitsubishi Tanabe Pharma Corporation, Lilly Diabetes, Ono Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Teijin Pharma Limited, Kyowa Kirin Co., Ltd., Daiichi Sankyo, Boehringer-Ingelheim, Sanofi. Y. Takeda: None. M. Takeuchi: None. K. Fujihara: None. H. Suzuki: Speaker's Bureau; Abbott Japan Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk, Kissei Pharmaceutical Co., Ltd., Kowa Company, Ltd., Boehringer-Ingelheim, Terumo Corporation, AstraZeneca, Bayer Inc., Kyowa Kirin Co., Ltd. N. Yoshioka: None. H. Shimano: None. J. Satoh: Speaker's Bureau; Lilly Diabetes, Merck & Co., Inc., Ono Pharmaceutical Co., Ltd., Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Boehringer-Ingelheim. Y. Hayashino: Speaker's Bureau; Eli Lilly and Company, Merck & Co., Inc., Boehringer-Ingelheim, Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk A/S. N. Tajima: None. R. Nishimura: Speaker's Bureau; Abbott. Advisory Panel; Abbott Japan Co., Ltd. Speaker's Bureau; Boehringer-Ingelheim, Mitsubishi Tanabe Pharma Corporation, Kowa Company, Ltd., Medtronic, Sanofi, Taiho Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co., Ltd., Teijin Pharma Limited, Eli Lilly and Company, Novo Nordisk A/S. Consultant; Terumo Corporation. Y. Yamasaki: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

Funding

The Japan Diabetes Society, the Japan Society for the Promotion of Science(23K10873).

DOI： 10.2337/db24-1372-p

researchmap

1474-P: Cross-Sectional and Longitudinal Relationships between Detailed Family History (FH) of Type 2 Diabetes Mellitus (T2DM), Hypertension (HT), and Dyslipidemia (DL) and Prevalence of Each Disorder

IZUMI IKEDA, KAZUYA FUJIHARA, YASUNAGA TAKEDA, MARIKO HATTA, SIJIA WU, SATORU KODAMA, YASUMICHI MORI, TAKASHI KADOWAKI, RITSUKO YAMAMOTO-HONDA, YASUJI ARASE, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

A FH of T2DM, HT, and DL are known risk factors; however, few studies have compared the impact of a FH of the 3 diseases in the same population. We examined the impact of a detailed FH of these conditions (i.e., in fathers, mothers, siblings and grandparents) on their prevalence and incidence in the study population. Data on 41,931 participants who underwent health checkups were examined and the results of a logistic regression and (Cox regression model in the same cohort were examined. Results of the cross-sectional study showed that odds ratios increased with the degree of a positive FH for all three diseases. Furthermore, in T2DM, the group with a three-generation positive FH was approximately 20 times larger than the control group which had no FH (Figure). In the longitudinal study, FH had a strong influence on the incidence of T2DM, HT, and DL, in that order, with a hazard ratio of 2.40 (1.93-2.98) for T2DM. A detailed FH was extremely useful for both quantitative screening for each disease and predicting the incidence of the three diseases, especially T2DM, for which a high risk was indicated in multiple generations with overlapping of positivity for a particular disease.

 Disclosure

I. Ikeda: None. K. Fujihara: None. Y. Takeda: None. M. Hatta: None. S. Wu: None. S. Kodama: None. Y. Mori: None. T. Kadowaki: None. R. Yamamoto-Honda: None. Y. Arase: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

DOI： 10.2337/db24-1474-p

researchmap

1259-P: Relationship between Number of Multiple Risk Factors and Functional Disability (FD) in Those With and Without Diabetes Mellitus (DM)

HARUKA SHIOZAKI, KAZUYA FUJIHARA, KAHORI TSURUOKA, IZUMI IKEDA, MASARU KITAZAWA, YASUHIRO MATSUBAYASHI, MASAHIKO YAMAMOTO, TAKAHO YAMADA, SATORU KODAMA, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Although control of multiple risk factors is essential to prevent FD with and without DM, longitudinal studies are scarce that directly and quantitatively compare effects of such control. Thus, we assessed whether reaching multifactorial targets for HbA1c, blood pressure, non-HDLC, and lifestyle risks such as smoking and no physical activity are associated with FD in those with and without DM.

Enrolled were 9652 Japanese aged 39-98 y. FD was defined based on the Japanese long-term care insurance system, and targets were based on ADA and Japanese guidelines.

Of 8,861 non-DM persons, 6.3, 25.2 and 49.1% were on target for 0-2, 3 and 4 factors, respectively. Of 791 persons with DM, 12.4, 68.0 and 19.3% were on target for 0-2, 3-4 and 5 factors, respectively.

Multivariate Cox analysis showed increased FD with decreased targets reached regardless of DM (Table, upper). Compared with people with non-DM who achieved 4 targets, non-DM persons who achieved 0 to 2 targets and DM persons who achieved 3 to 4 targets had nearly twice the incidence of FD (Table, lower). Moreover, people with DM who achieved only 0 to 2 targets had an approximately 4 times higher incidence of FD (Table, lower). Control of modifiable risk factors was effective regardless of DM. Achievement of all 5 targets among people with DM may reduce FD to the same level as in non-DM persons who achieved all 4 targets.

 Disclosure

H. Shiozaki: None. K. Fujihara: None. K. Tsuruoka: None. I. Ikeda: None. M. Kitazawa: None. Y. Matsubayashi: None. M. Yamamoto: None. T. Yamada: None. S. Kodama: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

Funding

the Japan Society for the Promotion of Science (21K11569); Daiwa Securities Health Foundation

DOI： 10.2337/db24-1259-p

researchmap

1666-P: Effect of Obesity in Family History (FH) on the Prevalence of Type 2 Diabetes Mellitus (T2DM), Hypertension (HT), and Dyslipidemia (DL)

IZUMI IKEDA, KAZUYA FUJIHARA, YASUNAGA TAKEDA, CHIKA HORIKAWA, SATORU KODAMA, EFREM D. FERREIRA, YASUMICHI MORI, TAKASHI KADOWAKI, RITSUKO YAMAMOTO-HONDA, YASUJI ARASE, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Heritability and obesity are strongly associated with the prevalence of T2DM, HT, and DL. We compared the effects of an FH of T2DM, HT, and DL combined with obesity on the prevalence of each in the same population. Of 41931 participants who underwent health checkups, the effects of an FH and BMI on the prevalence of those conditions were analyzed cross-sectionally. Prevalences of T2DM, HT, and DL were 5%, 20%, and 48%, respectively. Logistic regression analysis showed that ORs increased for all three as the number of FH positive cases increased and was most pronounced for T2DM. An FH of obesity and increased BMI were additively associated with the prevalence of the three diseases compared to BMI 20.0-21.9 and no positive FH (Fig. A). In addition, the combination of the number of family members with FH positivity (0,1, 2, ≥3) and obesity was additively associated with an increased FH of the three diseases compared to non-obesity and no FH of any of these diseases (Fig. B). For T2DM, the OR increased sharply in non-obese participants when the number of those with an FH of T2DM was ≥3 (14.4 [8.88-23.5]), but in obese participants the OR increased sharply when the number of those with an FH of T2DM was 2 (12.2 [8.85-16.9]) (Fig. B). Results suggest that, especially for T2DM, avoidance of obesity may be effective in reducing the prevalence of these disorders in those with many FH-positive family members.

 Disclosure

I. Ikeda: None. K. Fujihara: None. Y. Takeda: None. C. Horikawa: None. S. Kodama: None. E.D. Ferreira: None. Y. Mori: None. T. Kadowaki: None. R. Yamamoto-Honda: None. Y. Arase: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

DOI： 10.2337/db24-1666-p

researchmap

Usefulness of New Criteria for Metabolic Syndrome Optimized for Prediction of Cardiovascular Diseases in Japanese.

Yurie Yamazaki, Kazuya Fujihara, Takaaki Sato, Mayuko Harada Yamada, Yuta Yaguchi, Yasuhiro Matsubayashi, Takaho Yamada, Satoru Kodama, Kiminori Kato, Hitoshi Shimano, Hirohito Sone

Journal of atherosclerosis and thrombosis 31 ( 4 ) 382 - 395 2024.4

Language：English Publishing type：Research paper (scientific journal)

AIMS: We attempted to clarify whether the multiple criteria for metabolic syndrome (MetS) can sufficiently predict cardiovascular disease, whether waist circumference (WC) should be required, and whether sex-specific thresholds for each component are necessary. Only a few large-scale studies among East Asians have addressed the ability of MetS to predict cardiovascular disease. METHODS: We analyzed the data of 330,051 men and 235,028 women aged 18-74 years with no history of coronary artery disease (CAD) or cerebrovascular disease (CVD) from a nationwide Japanese claims database accumulated during 2008-2016. The association of each MetS component with CAD or CVD (CAD/CVD), MetS associated with CAD/CVD according to various criteria, and utility of modified criteria with more specific optimal values for each component were examined using multivariate Cox regression and receiver operating characteristic (ROC) analysis. RESULTS: During the study, 3,934 men (1.19%) and 893 women (0.38%) developed CAD/CVD. For each current MetS criteria, there was a 1.3- to 2.9-fold increased risk of CAD/CVD. Optimal thresholds for predicting CAD/CVD were WCs of 83 and 77 cm, triglycerides levels of 130 and 90 mg/dl, high-density lipoprotein cholesterol levels of 50 and 65 mg/dl, blood pressures of 130/80 and 120/80 mmHg, and fasting plasma glucose levels of 100 and 90 mg/dl for men and women, respectively. The existing MetS criteria and modified criteria were not significantly different in predicting CAD/CVD, but using the modified criteria markedly increased the prevalence of MetS and percentage of people with MetS developing CAD/CVD. CONCLUSIONS: Although various criteria for MetS similarly predicted CAD/CVD, the new criteria greatly reduced the number of high-risk individuals, especially women, overlooked by the current criteria.

DOI： 10.5551/jat.64380

PubMed

researchmap

糖尿病(DM)の有無別にみた生活習慣関連因子(Cardiovascular Health Metrics)が腎透析導入(HD)に及ぼす影響の検討

大澤妙子, 藤原和哉, 山田万祐子, 矢口雄大, 佐藤隆明, 北澤勝, 松林泰弘, 山田貴穂, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 168 2024.4

糖尿病患者における重症合併症の複合アウトカム(CSDC)の発症リスク因子の検討

田中菜々子, 矢口雄大, 佐藤隆明, 大澤妙子, 鈴木浩史, 山田貴穂, 藤原和哉, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 186 2024.4

代謝異常を伴う脂肪肝(MASLD)サブタイプのトランジションとCVD新規発症との関連について

松林泰弘, 藤原和哉, 山田万祐子, 佐藤隆明, 矢口雄大, 山本正彦, 石黒創, 大澤妙子, 北澤勝, 山田貴穂, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 215 2024.4

新規開発した総合体力指標フィジカルスコアによる各種代謝疾患の発症予測能の検討

佐藤隆明, 藤原和哉, 矢口雄大, 山本正彦, 北澤勝, 鈴木浩史, 松林泰弘, 石黒創, 大澤妙子, 山田貴穂, 加藤公則, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 216 2024.4

糖尿病予備群(preDM)におけるHbA1c,空腹時血糖(FPG)およびそれらの組み合わせによる脳心血管疾患(CVD)発症リスクの関連

村井幸四郎, 藤原和哉, 山田万祐子, 矢口雄大, 北澤勝, 山本正彦, 佐藤隆明, 松林泰弘, 山田貴穂, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 247 2024.4

メタボリックシンドローム(MetS)の経年的変化と心血管疾患発症の関連

滝澤大輝, 藤原和哉, 三ツ間友里恵, 山田万祐子, 村井幸四郎, 佐藤隆明, 矢口雄大, 山本正彦, 大澤妙子, 北澤勝, 松林泰弘, 岩永みどり, 山田貴穂, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 249 2024.4

日本人2型糖尿病患者における,飽和脂肪酸エネルギー比率と心血管疾患発症との関係 JDCP studyの解析から

堀川千嘉, 高原充佳, 片上直人, 武田安永, 竹内瑞希, 藤原和哉, 鈴木浩明, 津田謹輔, 吉岡成人, 島野仁, 佐藤譲, 林野泰明, 田嶼尚子, 西村理明, 山崎義光, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 169 2024.4

PHRスマートフォンアプリとisCGMを連動させた2型糖尿病発症予防プログラムの有効性検証のためのランダム化比較試験

北澤勝, 武田安永, 治田麻理子, 堀川千嘉, 佐藤隆明, 大澤妙子, 石澤正博, 鈴木浩史, 松林泰弘, 藤原和哉, 山田貴穂, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 216 2024.4

詳細な家族歴が2型糖尿病,高血圧,脂質異常症の有病と発症に与える影響の横断縦断的検討

池田和泉, 五十嵐理沙, 藤原和哉, 武田安永, 松林泰弘, 児玉暁, 山田貴穂, 森保道, 門脇孝, 本田律子, 荒瀬康司, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 194 2024.4

Higher dietary protein/energy ratio is associated with a lower risk for obesity in older women with type 2 diabetes: Cross-sectional analysis of Japanese patients with type 2 diabetes mellitus

Efrem d'Ávila Ferreira, Mariko Hatta, Khin Laymon, Izumi Ikeda, Mizuki Takeuchi, Yasunaga Takeda, Sakiko Yoshizawa Morikawa, Chika Horikawa, Noriko Kato, Hiroshi Maegawa, Kazuya Fujihara, Hirohito Sone

Human Nutrition & Metabolism 200257 - 200257 2024.3

Cross-Sectional and Longitudinal Associations between Forearm Bone Mineral Density and Anthropometry in Adult Japanese Men and Women

Masahiro Ishizawa, Kazuya Fujihara, Junko Yachida, Izumi Ikeda, Takaaki Sato, Takaho Yamada, Ayako Kobayashi, Shiro Tanaka, Yoshimi Nakagawa, Takashi Matsuzaka, Hitoshi Shimano, Minoru Tashiro, Satoru Kodama, Kiminori Kato, Hirohito Sone

Journal of Bone Metabolism 31 ( 1 ) 21 - 30 2024.2

Publishing type：Research paper (scientific journal)

Background: No consensus exists regarding which anthropometric measurements are related to bone mineral density (BMD), and this relationship may vary according to sex and age. A large Japanese cohort was analyzed to provide an understanding of the relationship between BMD and anthropometry while adjusting for known confounding factors. Methods: Our cohort included 10,827 participants who underwent multiple medical checkups including distal forearm BMD scans. Participants were stratified into four groups according to age (≥50 years or <50 years) and sex. The BMD values were adjusted for confounding factors, after which single and partial correlation analyses were performed. The prevalence of osteopenia was plotted for each weight index (weight or body mass index [BMI]) class. Results: Cross-sectional studies revealed that weight was more favorably correlated than BMI in the older group (R=0.278 and 0.212 in men and R=0.304 and 0.220 in women, respectively), whereas weight and BMI were weakly correlated in the younger age groups. The prevalence of osteopenia exhibited a negative linear relationship with weight among older women ≥50 years of age, and an accelerated increase was observed with decreasing weight in older men weighing <50 kg and younger women weighing <60 kg. When weight was replaced with BMI, the prevalence was low in most subgroups classified by weight. Conclusions: Weight, rather than BMI, was the most important indicator of osteopenia but it might not be predictive of future bone loss.

DOI： 10.11005/jbm.2024.31.1.21

Scopus

researchmap

機能性甲状腺結節による甲状腺中毒症を誘因として糖尿病性ケトアシドーシスを来し甲状腺クリーゼを発症した一例

間島貴之, 鈴木浩史, 木村智佑, 佐藤隆明, 山本雅彦, 石黒創, 岩永みどり, 松林泰弘, 山田貴穂, 藤原和哉, 曽根博仁

日本内分泌学会雑誌 99 ( 4 ) 884 - 884 2024.1

機能性甲状腺結節による甲状腺中毒症を誘因として糖尿病性ケトアシドーシスを来し甲状腺クリーゼを発症した一例

間島貴之, 鈴木浩史, 木村智佑, 佐藤隆明, 山本雅彦, 石黒創, 岩永みどり, 松林泰弘, 山田貴穂, 藤原和哉, 曽根博仁

日本内分泌学会雑誌 99 ( 4 ) 884 - 884 2024.1

副交感神経障害を伴わず糖尿病性動眼神経麻痺との鑑別に難渋した下垂体卒中による動眼神経麻痺の一例

深井悠未, 村井幸四郎, 今西明, 矢口雄大, 北澤勝, 鈴木浩史, 松林泰弘, 藤原和哉, 岩永みどり, 山田貴穂, 曽根博仁, 岡田正康

日本内分泌学会雑誌 99 ( 4 ) 895 - 895 2024.1

　 PREV - NEXT 　

<FUJIHARA Kazuya>

Papers - FUJIHARA Kazuya